ArticlePloS one2026
Association of 18F-fluorodeoxyglucose uptake with cardiac events in cardiac sarcoidosis during outpatient follow-up after immunosuppression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is a pivotal tool for diagnosing cardiac sarcoidosis, but its prognostic value during the phase of stable medical and device therapy after initiation of immunosuppressive therapy remains unclear. We aimed to evaluate the prognostic significance of cardiac FDG uptake in patients with cardiac sarcoidosis after treatment initiation.
methodsWe retrospectively analyzed 79 patients who underwent FDG-PET/CT ≥ 12 months after initiating immunosuppressive therapy (June 2013-October 2023). Patients were categorized into the cardiac accumulation (+) and (-), and Cardiac metabolic activity (CMA) was also quantitatively measured. Major adverse cardiac events-including cardiac death, ventricular arrhythmias, ICD therapy, and heart failure hospitalization-were evaluated.
resultsPatients in the cardiac accumulation (+) had a higher 2-year incidence of major adverse cardiac events than those in the cardiac accumulation (-), as determined by Kaplan-Meier analysis (log-rank P = 0.030), but FDG uptake was not identified as a predictor in Cox regression analysis. In long-term outcomes, the incidence of cardiac events tended to be higher in the cardiac accumulation (+) group, although this difference did not reach statistical significance (log-rank P = 0.078). Among patients with preserved left ventricular ejection fraction (LVEF ≥50%, independently associated with fewer events), annual cardiac event rates were similarly low regardless of uptake status (1.3% vs. 0.8%; log-rank P = 0.91). In 41 patients who underwent repeat PET imaging, CMA significantly decreased (median 4.83 to 0.82, P = 0.038). Among 23 patients without intensified immunosuppression despite uptake, it resolved spontaneously in 8 patients.
conclusionsFollow-up cardiac FDG uptake may be associated with an increased risk of short-term events but has limited value for predicting long-term prognosis. LVEF and the temporal dynamics of FDG uptake should be considered when managing cardiac sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.